Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 13/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 2/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583109 | 1.00 | OPRM1 (0.52) | OPRM1OPRK1OPRL1OPRD1CALCRL | |
| SCHEMBL3587909 | 0.84 | CHRM1 (0.63) | OPRM1OPRK1OPRL1OPRD1DRD2 | |
| SCHEMBL3595370 | 0.84 | CHRM1 (0.63) | OPRM1OPRK1OPRL1OPRD1DRD2 | |
| SCHEMBL3584064 | 0.84 | CHRM1 (0.63) | OPRM1OPRK1OPRL1OPRD1DRD2 | |
| SCHEMBL3585876 | 0.83 | OPRL1 (0.62) | OPRM1OPRK1OPRL1OPRD1CALCRL | |
| SCHEMBL3585881 | 0.83 | OPRL1 (0.62) | OPRM1OPRK1OPRL1OPRD1CALCRL | |
| SCHEMBL3591112 | 0.81 | CHRM1 (0.65) | OPRM1OPRK1OPRL1OPRD1DRD2 | |
| SCHEMBL1700324 | 0.78 | CALCRL (0.56) | OPRM1OPRK1OPRL1OPRD1CALCRL | |
| SCHEMBL3599215 | 0.77 | CHRM1 (0.62) | OPRM1OPRK1OPRL1OPRD1DRD2 | |
| SCHEMBL15205127 | 0.77 | TNKS (0.61) | OPRM1OPRK1OPRL1OPRD1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2128154-B1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | OPRM1 55/4885OPRK1 133/4885OPRL1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.